Iq Eq Fund Management (Ireland) LTD Nurix Therapeutics, Inc. Transaction History
Iq Eq Fund Management (Ireland) LTD
- $1.4 Billion
- Q3 2025
A detailed history of Iq Eq Fund Management (Ireland) LTD transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Iq Eq Fund Management (Ireland) LTD holds 42,759 shares of NRIX stock, worth $547,315. This represents 0.03% of its overall portfolio holdings.
Number of Shares
42,759
Previous 26,406
61.93%
Holding current value
$547,315
Previous $300,000
31.67%
% of portfolio
0.03%
Previous 0.03%
Shares
3 transactions
Others Institutions Holding NRIX
# of Institutions
184Shares Held
77.6MCall Options Held
99.8KPut Options Held
11.3K-
Black Rock Inc. New York, NY6.82MShares$87.3 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT6.06MShares$77.5 Million1.77% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.49MShares$57.5 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY3.88MShares$49.7 Million0.29% of portfolio
-
Commodore Capital LP New York, NY3.78MShares$48.4 Million2.23% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $603M
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...